Results 71 to 80 of about 7,072 (218)

Heart failure : studies of prognosis and advanced therapy [PDF]

, 2017
Background Heart failure (HF) is a major health problem affecting 2-3% of the Western population. The clinical syndrome of HF is associated with reduced (HFrEF) or preserved (HFpEF) ejection fraction.
Thorvaldsen, Tonje
core   +1 more source

Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction [PDF]

, 2020
Heart failure with mid-range ejection fraction (HFmrEF) has been proposed as a distinct HF phenotype, but whether patients on this category fare worse, similarly, or better than those with HF with reduced EF (HFrEF) or preserved EF (HFpEF) in terms of ...
Amiguet, Martina, Bayés-Genís, Antoni, Chorro, Francisco J., De la Espriella, Rafael, Lupón, Josep, Miñana, Gema, Núñez Villota, Julio, Palau, Patricia, Sanchis, Juan, Santas, Enrique, Universitat Autònoma de Barcelona   +10 more
core   +2 more sources

The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction [PDF]

, 2021
Heart failure (HF) with mid-range or preserved ejection fraction (HFmrEF; HFpEF) is a heterogeneous disorder that could benefit from strategies to identify subpopulations at increased risk.
Gorter, Thomas M., Op den Akker, Jeroen W., Peters, Aniek, Pundziute, Gabija, Rienstra, Michiel, van Empel, Vanessa P. M., van Veldhuisen, Dirk J., van Woerden, Gijs, Westenbrink, B. Daan, Willems, Tineke P.   +9 more
core   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Correlation of NT-proBNP Levels with Outcome in Patients of Acute Decompensated Heart Failure

Indian Journal of Medical Specialities
Background: Acute decompensated heart failure (ADHF) is a significant contributor to morbidity and mortality globally, particularly in resource-limited settings like India.
Dheeraj Balotia, Anshuman Srivastava, Amitesh Aggarwal, Alpana Raizada, Rahul Sharma   +4 more
doaj   +1 more source

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed, Daniel Mølager Christensen, Milan Mohammad, Christian Torp‐Pedersen, Lars Køber, Emil Loldrup Fosbøl, Tor Biering‐Sørensen, Morten Lock Hansen, Mariam Elmegaard Malik, Nina Nouhravesh, Charlotte Anderrson, Morten Schou, Gunnar Gislason   +12 more
wiley   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF

International Journal of Heart Failure
Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF are heterogeneous conditions requiring precision phenotyping to enable tailored therapies.
Giuseppe M.C. Rosano, Cristiana Vitale, Ilaria Spoletini   +2 more
openaire   +2 more sources

Inflammation, Immunity, and Cardiovascular Diseases

Med Research, EarlyView.
Cardiovascular stress signals (e.g., hemodynamic shear, oxidized lipids, and ischemia) act on endothelial and immune cells to activate and amplify inflammation through NF‐κB, the NLRP3 inflammasome, and JAK/STAT signaling, inducing proinflammatory cytokines/chemokines (IL‐6, IL‐1β, TNF‐α, and CCL2) and self‐amplifying circuits; clinically, inflammatory
Dezhi Guo, Yan Liao, Rui Zhao, Zhaoyu Li, Kaikai Wang, Haoling Zhang, Pingxin Sun, Yadong Guo, Wangzheqi Zhang   +8 more
wiley   +1 more source

Impact of diastolic dysfunction on outcome in heart failure patients with mid‐range or reduced ejection fraction

ESC Heart Failure, 2021
Aims The role of diastolic dysfunction (DD) in prognostic evaluation in heart failure (HF) patients with impaired systolic function remains unclear.
Dan Liu, Kai Hu, Kolja Lau, Tobias Kiwitz, Katharina Robitzkat, Clara Hammel, Björn Daniel Lengenfelder, Georg Ertl, Stefan Frantz, Peter Nordbeck   +9 more
doaj   +1 more source